Zanolimumab: Difference between revisions
Content deleted Content added
No edit summary |
m WP:CHECKWIKI error #61 fix and general fixes, References after punctuation per WP:CITEFOOT and WP:PAIC using AWB (8463) |
||
Line 49: | Line 49: | ||
| molecular_weight = 147 [[kDa]] |
| molecular_weight = 147 [[kDa]] |
||
}} |
}} |
||
'''Zanolimumab''' (expected trade name '''HuMax-CD4'''<ref>[http://www.genmab.com/PressCentre/ArchivedNewsReleases/2000/GenmabInitiatesPhaseIIStudyWithHuMax-CD4/Language/English.aspx Genmab initiates Phase II Study with HuMax-CD4]</ref>) is a [[human]] [[monoclonal antibody]] and an [[immunosuppressive drug]]. It is being developed for the treatment of [[rheumatoid arthritis]], [[psoriasis]], [[melanoma]],<ref>http://www.tenxbiopharma.com/development.shtml</ref> cutaneous and peripheral [[T-cell lymphoma]].<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/zanolimumab.doc Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab], ''American Medical Association''.</ref><ref>{{ClinicalTrialsGov|NCT00042406|Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker}}</ref> The drug is currently undergoing Phase II trials<ref>{{cite web|title=Status of clinical trials for Zanolimumab|url=http://clinicaltrials.gov/search/intervention=Zanolimumab|accessdate=6 November 2011}}</ref> |
'''Zanolimumab''' (expected trade name '''HuMax-CD4'''<ref>[http://www.genmab.com/PressCentre/ArchivedNewsReleases/2000/GenmabInitiatesPhaseIIStudyWithHuMax-CD4/Language/English.aspx Genmab initiates Phase II Study with HuMax-CD4]</ref>) is a [[human]] [[monoclonal antibody]] and an [[immunosuppressive drug]]. It is being developed for the treatment of [[rheumatoid arthritis]], [[psoriasis]], [[melanoma]],<ref>http://www.tenxbiopharma.com/development.shtml</ref> cutaneous and peripheral [[T-cell lymphoma]].<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/zanolimumab.doc Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab], ''American Medical Association''.</ref><ref>{{ClinicalTrialsGov|NCT00042406|Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker}}</ref> The drug is currently undergoing Phase II trials.<ref>{{cite web|title=Status of clinical trials for Zanolimumab|url=http://clinicaltrials.gov/search/intervention=Zanolimumab|accessdate=6 November 2011}}</ref> |
||
== References == |
== References == |
Revision as of 17:20, 15 October 2012
Emergent BioSolutions Acquires Rights Of Zanolimumab From TenX Biopharma
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | CD4 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Molar mass | 147 kDa |
(what is this?) (verify) |
Zanolimumab (expected trade name HuMax-CD4[1]) is a human monoclonal antibody and an immunosuppressive drug. It is being developed for the treatment of rheumatoid arthritis, psoriasis, melanoma,[2] cutaneous and peripheral T-cell lymphoma.[3][4] The drug is currently undergoing Phase II trials.[5]
References
- ^ Genmab initiates Phase II Study with HuMax-CD4
- ^ http://www.tenxbiopharma.com/development.shtml
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab, American Medical Association.
- ^ Clinical trial number NCT00042406 for "Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker" at ClinicalTrials.gov
- ^ "Status of clinical trials for Zanolimumab". Retrieved 6 November 2011.